Skip to main content

Advertisement

SpringerLink
Log in

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Glycolipids GM2, GD2, GD3, fucosyl GM1, sialyl Lewis a (sLea) and globo H, and polysialic acid on embryonal NCAM, are cell-surface antigens expressed on small cell lung cancer (SCLC) biopsy specimens. They are all candidates for inclusion in a polyvalent, antibody-inducing vaccine or for adoptive therapy with monoclonal antibodies (mAbs) against SCLC. To identify the minimum optimal combination of target antigens on SCLC and to confirm that antibodies against this combination might be able to mediate complement activation and lysis in the majority of cases, we tested ten SCLC cell lines with fluorescence activated cell sorter (FACS) and complement dependent cytotoxicity (CDC) assays using mAbs against these seven target antigens individually or pooled in different combinations. We find that (1) none of these mAbs demonstrated strong FACS reactivity with more than 6 of the 10 cell lines, (2) no mAb had strong CDC reactivity with more than 4 of the cell lines, (3) when the mAbs were pooled, nine cell lines were strongly positive by FACS and nine cell lines were strongly positive by CDC, and (4) mAbs against GM2, FucGM1, globo H and polysialic acid was the minimum optimal combination for inducing FACS reactivity. The addition of mAbs against sLea, GD2 and GD3 had no additional impact by FACS and only minimal additional impact in CDC assays. H345, the only cell line that had less than 30% CDC with the four mAb pool was strongly positive by FACS. To understand the lack of correlation between FACS and CDC in the case of H345, the ten cell lines were screened for expression of complement resistance factors CD55 and CD59. Three cell lines were strongly positive for CD55 and eight were strongly positive for CD59. Overall, no correlation was seen between expression of either of these factors on the ten cell lines and sensitivity to CDC. In the case of H345 however, complement resistance of H345 is demonstrated to be mediated primarily by CD59, and in the presence of mAb against CD59, the four mAb MEM-43 pool induced strong (94%) CDC. CD59 inhibits membrane attack complex formation but not activation of earlier complement components. Consequently, all ten cell lines are good targets for complement activation by the four antibody pool and for elimination by effector mechanisms including complement mediated inflammation and opsonization. These findings support our plan to develop a tetravalent vaccine against SCLC targeting GM2, fucosyl GM1, globo H and polysialic acid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brezicka FT, Olling S, Nilsson O, Bergh J, Holmgren J, Sorenson S, Yngvason F, Lindholm L (1989) Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res 49(5):1300–1305

    CAS  PubMed  Google Scholar 

  2. Brezicka T, Bergman B, Olling S, Fredman P (2000) Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. Lung Cancer 28(1):29–36

    Article  CAS  PubMed  Google Scholar 

  3. Caragine TA, Okada N, Frey AB, Tomlinson SA (2002) Tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res 62(4):1110–1115

    CAS  PubMed  Google Scholar 

  4. Chapman PB, Livingston P, Morrison ME, Williams L, Houghton AN (1994) Immunization of melanoma patients with antiidiotype monoclonal antibody bec2 (which mimics GD3 ganglioside): pilot trials using no immunological adjuvant. Vaccine Res 3(2):59–69

    Google Scholar 

  5. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA (1986) Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res 46(10):5112–5118

    CAS  PubMed  Google Scholar 

  6. Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME (1988) Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81(4):1122–1128

    CAS  PubMed  Google Scholar 

  7. Colten HR, Rosen FS (1992) Complement deficiencies. Annu Rev Immunol 10:809–834

    Article  CAS  PubMed  Google Scholar 

  8. Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC (1999) Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 5(10):2773–2779

    CAS  PubMed  Google Scholar 

  9. Giaccone G, Debruyne C, Felip E, Millward M, D’Addario G, Thiberville L, Rome L, Zatloukal P, Legrand C (2004) Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study). J Clin Oncol (Meeting Abstracts) 22(14_suppl):7020

    Google Scholar 

  10. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55(13):2783–2788

    CAS  PubMed  Google Scholar 

  11. Huntsberger DV, Leaverton P (1970) Statistical inference in the biomedical sciences. Allyn and Bacon Inc., Boston

    Google Scholar 

  12. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R, Meri S (1997) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 71(6):1049–1055

    Article  CAS  PubMed  Google Scholar 

  13. Joiner KA (1988) Complement evasion by bacteria and parasites. Annu Rev Microbiol 42:201–230

    Article  CAS  PubMed  Google Scholar 

  14. Komminoth P, Roth J, Lackie PM, Bitter-Suermann D, Heitz PU (1991) Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am J Pathol 139(2):297–304

    CAS  PubMed  Google Scholar 

  15. Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO (2004) Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10(3):916–923

    CAS  PubMed  Google Scholar 

  16. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO (2004) Vaccinatin of patients with small cell lung cancer with synthetic fucosyl GM1 conjugated to Keyhole Limpet Hemocyanin (KLH). Clin Cancer Res 10:6094–6102

    Google Scholar 

  17. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO (2005) Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 174:5706–5712

    CAS  PubMed  Google Scholar 

  18. Livingston P, Zhang S, Adluri S, Yao TJ, Graeber L, Ragupathi G, Helling F, Fleisher M (1997) Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 43(6):324–330

    Article  CAS  PubMed  Google Scholar 

  19. Moffitt MC, Frank MM (1994) Complement resistance in microbes. Springer Semin Immunopathol 15(4):327–344

    CAS  PubMed  Google Scholar 

  20. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129(1):184–189

    CAS  PubMed  Google Scholar 

  21. Nilsson O, Mansson JE, Brezicka T (1984) Fucosyl-GM1-A ganglioside associated with small cell lung carcinomas. Glycoconjugate 1:43–49

    CAS  Google Scholar 

  22. Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG, Danishefsky SJ, Livingston PO (2002) Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 20(7–8):1030–1038

    Article  CAS  PubMed  Google Scholar 

  23. Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO (2003) A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol Immunother 52(10):608–616

    Article  CAS  PubMed  Google Scholar 

  24. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ (2003) Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9(14):5214–5220

    CAS  PubMed  Google Scholar 

  25. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85(5):659–666

    Article  CAS  PubMed  Google Scholar 

  26. Ragupathi G, Slovin S, Adluri S, Sames D, Kim IJ, Kim HM, Spassova M, Bornmann W, Lloyd KO, Scher HI, Livingston PO, Danishefsky SJ (1999) A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle. Angew Chem Int Ed 38(4):563–566

    Article  CAS  Google Scholar 

  27. Sakuma T, Kodama K, Hara T, Eshita Y, Shibata N, Matsumoto M, Seya T, Mori Y (1993) Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma. Jpn J Cancer Res 84(7):753–759

    CAS  PubMed  Google Scholar 

  28. Scheidegger EP, Lackie PM, Papay J, Roth J (1994) In vitro and in vivo growth of clonal sublines of human small cell lung carcinoma is modulated by polysialic acid of the neural cell adhesion molecule. Lab Invest 70(1):95–106

    CAS  PubMed  Google Scholar 

  29. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI (1999) Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci 96:5710–5715

    Article  CAS  PubMed  Google Scholar 

  30. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 73(1):42–49

    Article  CAS  PubMed  Google Scholar 

  31. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO (1998) Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res 4(11):2669–2676

    CAS  PubMed  Google Scholar 

  32. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73(1):50–56

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Clinical Immunology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA

    P. O. Livingston, C. Hood, L. M. Krug, N. Warren, M. G. Kris, T. Brezicka & G. Ragupathi

Authors
  1. P. O. Livingston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Hood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. M. Krug
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Warren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. G. Kris
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Brezicka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Ragupathi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. O. Livingston.

Additional information

Supported by grants from the NIH (PO1CA33049), and the Lawrence and Selma Ruben Foundations.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Livingston, P.O., Hood, C., Krug, L.M. et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 54, 1018–1025 (2005). https://doi.org/10.1007/s00262-005-0663-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0663-8

Keywords

Search

Navigation